Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study

Risankizumab is a humanized monoclonal antibody that binds the p19 subunit of interleukin-23. It is approved for treatment of moderate-severe chronic plaque psoriasis. This retrospective study included 66 consecutive adults with moderate-to-severe psoriasis vulgaris treated with risankizumab in mono...

Descripción completa

Detalles Bibliográficos
Autores principales: BORRONI, Riccardo G., MALAGOLI, Piergiorgio, GARGIULO, Luigi, VALENTI, Mario, PAVIA, Giulia, FACHERIS, Paola, MORENGHI, Emanuela, DI CORTERANZO, Isotta Giunipero, NARCISI, Alessandra, ORTONCELLI, Michela, DAPAVO, Paolo, COSTANZO, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society for Publication of Acta Dermato-Venereologica 2021
Materias:
Clinical Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9455321/
https://www.ncbi.nlm.nih.gov/pubmed/34596230
http://dx.doi.org/10.2340/actadv.v101.283

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9455321/
https://www.ncbi.nlm.nih.gov/pubmed/34596230
http://dx.doi.org/10.2340/actadv.v101.283

Ejemplares similares